Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Bio Technology General - BTGC -- Ignore unavailable to you. Want to Upgrade?

To: Liatris Spicata who wrote (2000)	5/3/2000 7:44:00 AM
From: Jim Oravetz	Read Replies (1) \| Respond to of 2028

The "Other" income line was almost 14% of the total amount. I'm assuming that a lot of this number is from interest on the $ they have on hand, ready to spend on the new ($30M)production facility. The R&D budget was up >$700K. Could this be spending related to the new facility? As far as G&A, they are spending $ in the lawsuits with Genentech and now I see a legal dispute with Serono. Also, with the dual nature of BTGC operations - US and Israel, IMO, BTGC is building an empire of upper mgnt that may have overlapping functions. I'm quite surprised at the reduction in Marketing and sales expense. I recall Sims saying that the sales force was being built out to increase exposure. Maybe they just paid the salesmen and did not do any media advertising? Jim